NRG1-Fusion Lung Adenocarcinoma With a Partial Response to Afatinib
This lung cancer diagnosis at a glance
- Subtype
- Adenocarcinoma
- Biomarkers
- CD74-NRG1 fusion
- Sex
- female
- Treatment
- chemotherapy, immunotherapy and targeted therapy
- Outcome
- In Memory
Treatment course, step by step
- Previously received carboplatin and pemetrexed, followed by durvalumab and later nivolumab.
- Started afatinib through the TAPUR study in December 2020 after testing identified a CD74-NRG1 fusion.
What happened, in summary
A 58-year-old woman with lung adenocarcinoma had already received several systemic treatments before entering the TAPUR precision-medicine study. Her prior therapy included carboplatin and pemetrexed chemotherapy, durvalumab, and later nivolumab, with progression on nivolumab.
Genomic testing identified a CD74-NRG1 fusion in her tumor. Based on that finding, she started the targeted drug afatinib in December 2020. Her measurable tumors decreased by about 31%, meeting criteria for a partial response. The response lasted 24 weeks, and the cancer progressed after 32 weeks on afatinib.
No major treatment-related adverse events were recorded during the study treatment. She died in April 2022. Her case was one of several rare NRG1-fusion cancers treated with afatinib in the TAPUR study and demonstrated that a genomic finding can sometimes identify a treatment option even after multiple previous therapies.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Afatinib for Lung Cancer 37 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer